Gufic Biosciences Limited (GUFICBIO.BO)
INR 449.05
(0.28%)
INR 449.05
(0.28%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -190.72 Million | -265.87 Million | 1.06 Billion | 872.5 Million | 471.01 Million | 52.07 Million |
| Net Income | 861.35 Million | 797.04 Million | 958.4 Million | 442.31 Million | 226.87 Million | 219.4 Million |
| Depreciation & Amortization | 170.17 Million | 222.81 Million | 189.28 Million | 163.07 Million | 138.64 Million | 46.46 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -1.3 Billion | -1.35 Billion | -107.2 Million | 81.54 Million | 24.77 Million | -335.17 Million |
| Other non-cash items | 1.72 Billion | 66.8 Million | 21.9 Million | 185.57 Million | 80.71 Million | 121.37 Million |
| Investing Cash Flow | -1.03 Billion | -1.9 Billion | -945.89 Million | -66.92 Million | -425.3 Million | -129.94 Million |
| Investments in PPE | -1.12 Billion | -1.87 Billion | -874.53 Million | -123.99 Million | -398.49 Million | -130.83 Million |
| Acquisitions | 45.66 Million | 316 Thousand | 684 Thousand | - | 155 Thousand | 50 Thousand |
| Investment purchases | -10 Million | -7.76 Million | -77.74 Million | - | -32.85 Million | -2.94 Million |
| Sales/Maturities of investments | - | 9.86 Million | 83.43 Million | 51.49 Million | 38.73 Million | 6.73 Million |
| Other Investing Activities | 57.35 Million | -33.67 Million | -77.73 Million | 5.56 Million | -32.85 Million | -2.94 Million |
| Financing Cash Flow | 950 Million | 2.34 Billion | -62.43 Million | -786.18 Million | -42.06 Million | 77.09 Million |
| Debt repayment | -55.07 Million | -2.5 Billion | -60.77 Million | -731.81 Million | -126.4 Million | -66.16 Million |
| Dividends payments | -9.72 Million | -10.43 Million | -9.21 Million | -3.62 Million | -4.87 Million | -3.87 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 999.9 Million | - | - | - | - | - |
| Other Financing Activities | -5.6 Million | 4.85 Billion | 7.54 Million | -50.74 Million | 89.21 Million | 147.13 Million |
| Accounts receivables | -1.53 Billion | -553.16 Million | -231.93 Million | -189.9 Million | -167.17 Million | -350.81 Million |
| Accounts payables | 400.33 Million | -120.46 Million | 341.53 Million | 9.01 Million | 274.23 Million | 16.47 Million |
| Inventory | -170.24 Million | -678.9 Million | -211.62 Million | 280.56 Million | -82.27 Million | -836 Thousand |
| Other working capital | 400.33 Million | - | -5.18 Million | -18.14 Million | - | -1000.00 |
| Cash at beginning of period | 286.24 Million | 116.08 Million | 62.01 Million | 42.61 Million | 38.96 Million | 37.39 Million |
| Cash at end of period | 134.84 Million | 286.01 Million | 116.08 Million | 62.01 Million | 42.61 Million | 36.61 Million |
| Capital Expenditure | -1.12 Billion | -1.87 Billion | -874.53 Million | -123.99 Million | -398.49 Million | -130.83 Million |
| Effect of forex changes on cash | - | - | - | - | -1000.00 | - |
| Net cash flow / Change in cash | -151.4 Million | 169.93 Million | 54.06 Million | 19.4 Million | 3.64 Million | -776 Thousand |
| Free Cash Flow | -1.31 Billion | -2.14 Billion | 187.86 Million | 748.51 Million | 72.52 Million | -78.76 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 861.35 Million | 222.57 Million | 232.09 Million | 206.22 Million | 797.04 Million | 181.05 Million |
| Depreciation & Amortization | 170.17 Million | 41.41 Million | 42.97 Million | 42.36 Million | 222.81 Million | 59.18 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -1.3 Billion | - | - | - | -1.35 Billion | - |
| Other non-cash items | 1.72 Billion | -181.15 Million | -42.97 Million | -42.36 Million | 66.8 Million | -59.18 Million |
| Investing Cash Flow | -1.03 Billion | - | - | - | -1.9 Billion | - |
| Investments in PPE | -1.12 Billion | - | - | - | -1.87 Billion | - |
| Acquisitions | 45.66 Million | - | - | - | 316 Thousand | - |
| Investment purchases | -10 Million | - | - | - | -7.76 Million | - |
| Sales/Maturities of investments | - | - | - | - | 9.86 Million | - |
| Other Investing Activities | 57.35 Million | - | - | - | -33.67 Million | - |
| Financing Cash Flow | 950 Million | - | - | - | 2.34 Billion | - |
| Debt repayment | -55.07 Million | - | - | - | -2.5 Billion | - |
| Dividends payments | -9.69 Million | - | - | - | -10.43 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 999.9 Million | - | - | - | - | - |
| Other Financing Activities | -5.6 Million | - | - | - | 4.85 Billion | - |
| Accounts receivables | -1.53 Billion | - | - | - | -553.16 Million | - |
| Accounts payables | 400.33 Million | - | - | - | -120.46 Million | - |
| Inventory | -170.24 Million | - | - | - | -678.9 Million | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 286.24 Million | 163.17 Million | -68.92 Million | 286.24 Million | 116.08 Million | 105.18 Million |
| Cash at end of period | 134.84 Million | 246 Million | 163.17 Million | 206.22 Million | 286.01 Million | 286.24 Million |
| Capital Expenditure | -1.12 Billion | - | - | - | -1.87 Billion | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -151.4 Million | 82.83 Million | 232.09 Million | -80.01 Million | 169.93 Million | 181.05 Million |
| Free Cash Flow | -1.31 Billion | 82.83 Million | 232.09 Million | 206.22 Million | -2.14 Billion | 181.05 Million |
002790
LSPK
AUST
SLMN
MKP
7155